Literature DB >> 8712932

Deletion of the carboxy-terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B does not affect oligomerization, heparin-binding activity, or its ability to protect against HSV challenge.

X H Lin1, M A Ali, H Openshaw, E M Cantin.   

Abstract

A recombinant vaccinia virus designated VgBt which expresses a truncated secreted herpes simplex virus gB (gBt) was constructed and compared to V11gB, a vaccinia recombinant previously studied which expresses gB exclusively on the surface of infected cells. Indirect immunofluorescence assay (IFA) revealed that gBt was strongly associated with the surface of infected cells despite being released slowly into the cell culture medium. Both gB and gBt existed as oligomers, and both membrane bound and secreted forms of gBt exhibited heparin-binding activity. In protection studies VgBt and V11gB conferred equivalent protection against both homologous (HSV-1) and heterologous (HSV-2) challenge with HSV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8712932     DOI: 10.1007/BF01718618

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  30 in total

1.  Oligomerization of herpes simplex virus glycoprotein B occurs in the endoplasmic reticulum and a 102 amino acid cytosolic domain is dispensable for dimer assembly.

Authors:  M A Ali
Journal:  Virology       Date:  1990-10       Impact factor: 3.616

2.  Anatomy of the herpes simplex virus 1 strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibody-resistant mutants.

Authors:  P E Pellett; K G Kousoulas; L Pereira; B Roizman
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

3.  The nucleotide sequence of the gB glycoprotein gene of HSV-2 and comparison with the corresponding gene of HSV-1.

Authors:  D J Bzik; C Debroy; B A Fox; N E Pederson; S Person
Journal:  Virology       Date:  1986-12       Impact factor: 3.616

4.  Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration.

Authors:  S L Highlander; W H Cai; S Person; M Levine; J C Glorioso
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

5.  A virion-associated glycoprotein essential for infectivity of herpes simplex virus type 1.

Authors:  S P Little; J T Jofre; R J Courtney; P A Schaffer
Journal:  Virology       Date:  1981-11       Impact factor: 3.616

6.  Nucleotide sequence specifying the glycoprotein gene, gB, of herpes simplex virus type 1.

Authors:  D J Bzik; B A Fox; N A DeLuca; S Person
Journal:  Virology       Date:  1984-03       Impact factor: 3.616

7.  Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B.

Authors:  M R McDermott; F L Graham; T Hanke; D C Johnson
Journal:  Virology       Date:  1989-03       Impact factor: 3.616

8.  Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.

Authors:  E M Cantin; R Eberle; J L Baldick; B Moss; D E Willey; A L Notkins; H Openshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

9.  Domains of herpes simplex virus I glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion.

Authors:  D Navarro; P Paz; L Pereira
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

10.  A recombinant vaccinia virus expressing herpes simplex virus type 1 glycoprotein B induces cytotoxic T lymphocytes in mice.

Authors:  E McLaughlin-Taylor; D E Willey; E M Cantin; R Eberle; B Moss; H Openshaw
Journal:  J Gen Virol       Date:  1988-07       Impact factor: 3.891

View more
  1 in total

1.  Herpes simplex virus 1 (HSV-1) strain HSZP glycoprotein B gene: comparison of mutations among strains differing in virulence.

Authors:  J Kosovský; A Vojvodová; I Oravcová; M Kúdelová; J Matis; J Rajcáni
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.